JREE:XETRA:XETRA-JPMorgan ETFs (Ireland) ICAV - Europe Research Enhanced Index Equity UCITS ETF - EUR (acc) (EUR)

ETF | Others |

Last Closing

USD 46.095

Change

+0.22 (+0.48)%

Market Cap

N/A

Volume

8.70K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-18 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

-0.15 (-0.33%)

USD 96.80B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.40 (-0.41%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-0.08 (-0.32%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

-0.07 (-0.53%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

-0.02 (-0.37%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

-0.12 (-0.52%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

-0.08 (-0.60%)

USD 23.43B
PPFB:XETRA iShares Physical Gold ETC EUR

+0.62 (+1.16%)

USD 19.49B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

-0.02 (-0.21%)

USD 12.83B
EUN5:XETRA iShares Core Corporate Bond UC..

+0.03 (+0.02%)

USD 12.26B

ETFs Containing JREE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.38% 87% B+ 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.38% 88% B+ 81% B-
Trailing 12 Months  
Capital Gain 10.85% 76% C+ 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.85% 76% C+ 72% C
Trailing 5 Years  
Capital Gain 120.71% 76% C+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 120.71% 77% C+ 72% C
Average Annual (5 Year Horizon)  
Capital Gain 12.95% 74% C 72% C
Dividend Return 12.95% 73% C 71% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.91% 54% F 63% D
Risk Adjusted Return 108.75% 92% A 93% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike